AmpliPhi Biosciences announces Baxter Phillips as VP of corporate strategy and business development
US-headquartered biotech company AmpliPhi BioSciences (OTCBB: APHB) has appointed Baxter Phillips III to the newly created position of vice president, corporate strategy and business development.
Mr Phillips has more than 15 years of experience in leading multinational corporate strategy efforts and structuring, negotiating, and executing strategic alliances, licenses and collaborations in the biotechnology and pharmaceutical industry. Based in the US, he will lead a variety of corporate and business development initiatives at AmpliPhi.
Philip Young, president and chief executive, said: “Baxter’s diverse background and successful global experiences in strategy, finance and licensing, will help accelerate AmpliPhi’s corporate initiatives as we continue our progress and growth to become the leading bacteriophage Company developing and delivering novel antibiotic therapies.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze